Background. Comparative data of non-vitamin K antagonist oral anticoagulants (NOAC) are lacking in patients with atrial fibrillation (AF).
Objective. We compared effectiveness and safety of standard and reduced dose NOAC in AF patients.
Methods. Using Danish nationwide registries, we included all oral anticoagulant-na€ ıve AF patients who initiated NOAC treatment (2012) (2013) (2014) (2015) (2016) . Outcome-specific and mortality-specific multiple Cox regressions were combined to compute average treatment effects as 1-year standardized differences in stroke and bleeding risks (g-formula).
Results. Amongst 31 522 AF patients, the distribution of NOAC/dose was as follows: dabigatran standard dose (22.4%), dabigatran-reduced dose (14.0%), rivaroxaban standard dose (21.8%), rivaroxaban reduced dose (6.7%), apixaban standard dose (22.9%), and apixaban reduced dose (12.2%). The 1-year standardized absolute risks of stroke/thromboembolism were 1.73-1.98% and 2.51-2.78% with standard and reduced NOAC dose, respectively, without statistically significant differences between NOACs for given dose level. Comparing standard doses, the 1-year standardized absolute risk (95% CI) for major bleeding was for rivaroxaban 2.78% (2.42-3.17%); corresponding absolute risk differences (95% CI) were for dabigatran À0.93% (À1.45% to À0.38%) and apixaban, À0.54% (À0.99% to À0.05%). The results for major bleeding were similar for reduced NOAC dose. The 1-year standardized absolute risk (95% CI) for intracranial bleeding was for standard dose dabigatran 0.19% (0.22-0.50%); corresponding absolute risk differences (95% CI) were for rivaroxaban 0.23% (0.06-0.41%) and apixaban, 0.18% (0.01-0.34%).
Conclusions. Standard and reduced dose NOACs, respectively, showed no significant risk difference for associated stroke/thromboembolism. Rivaroxaban was associated with higher bleeding risk compared with dabigatran and apixaban and dabigatran was associated with lower intracranial bleeding risk compared with rivaroxaban and apixaban.
Introduction
Patients with non-valvular atrial fibrillation (AF) at increased risk of stroke are recommended oral anticoagulant (OAC) treatment as stroke prophylaxis [1] . For decades, the only OAC option was vitamin K antagonist (VKA), for example warfarin. As introduction of non-VKA oral anticoagulants (NOACs), the initiation rates and the utilization patterns have changed, [2] [3] [4] [5] and in 2015, AF patients were more frequently initiated on NOACs than VKA treatment for stroke prophylaxis in Denmark [2] . Current AF guidelines also advocate NOACs over VKA [1] due to lower intracranial bleeding rates, no need for continuous anticoagulation monitoring and dose adjustment, and fewer drug-drug interactions, when compared with VKA [6] [7] [8] [9] [10] .
Most prior studies have primarily focused on the comparison of NOACs versus VKA [6] [7] [8] [9] [10] [11] [12] [13] . The diversely designed Phase III randomized controlled trials (RCTs) make it difficult to directly compare efficacy and safety of the NOACs, and there are no head-to-head trials comparing individual NOAC against each other [6] [7] [8] [9] . Moreover, in the Phase III RCTs for rivaroxaban and apixaban, there was no randomized arm of high or low dose NOAC, [7, 8] in contrast to the dabigatran and edoxaban Phase III RCTs [6, 9] . Nonetheless, AF guidelines recommend dose reductions of NOAC in selected patients, which is not based on solid evidence from Phase III RCTs [1] . Notably, there is a gap in knowledge about the efficacy and safety of reduced dose NOAC despite the disproportionately high usage of reduced dose NOAC, which is a cause of concern [14] . Therefore, studies examining the effectiveness and safety of standard dose or reduced dose NOAC in direct comparisons are warranted.
Our study aimed to compare first standard dose dabigatran, rivaroxaban and apixaban, and secondly, reduced dose dabigatran, rivaroxaban and apixaban, and the associated risks of thrombotic and bleeding outcomes.
Materials and methods

Data source
All citizens in Denmark are allocated a unique personal identification number, which we used to cross-link data on individual level from the following administrative registries: (i) The Danish National Patient Register holds information on all hospital contacts. Each hospital contact is coded with diagnosis codes according to the International Classification of Disease System 10th revision (ICD-10); [15] (ii) The Danish Register of Medicinal Product Statistics keeps track of all filled prescriptions including expedition date, package size and dispensed dosage; [16] and (iii) The Danish Civil Registration System administrates data on vital status [17] .
Study population
In Denmark, dabigatran was approved 22 August 2011, rivaroxaban on 6 February 2012 and apixaban on 10 December 2012. Patients were included if they had an AF diagnosis and subsequently filled a first-time prescription of OAC between 1 March 2012 and 31 December 2016. Inclusion day was the day a first-time prescription of OAC was filled. The AF diagnosis code has been validated in The Danish National Patient Register with a high positive predicted value [18] . Exclusion criteria are displayed in Fig. 1 .
Comorbidities and concomitant pharmacotherapy
We identified comorbidities from ICD-10 codes recorded within 10 years prior to inclusion day and concomitant pharmacotherapy from prescriptions filled within 180 days prior to inclusion day (ICD-10 and ATC codes are listed in Table S1 ), as described previously [2, 10] .
At time of inclusion in the study, stroke and bleeding risk stratification scores were calculated according to the CHA 2 DS 2 -VASc and HAS-BLED scores, respectively (Table S2 ).
Outcomes
Outcomes of interest were stroke/thromboembolism (TE), ischaemic stroke, major bleeding, intracranial bleeding and gastrointestinal bleeding (ICD-10 codes are listed in Table S1 ). Validation studies have shown high positive predictive values for stroke and bleeding [19, 20] . The 2-year followup period began at day of inclusion and patients were followed until the occurrence of outcome, death, emigration, shift or discontinuation of initiated treatment, or 31 December 2016, whichever came first. Shift was defined as if a patient shifted treatment from the initiated NOAC agent to another NOAC or VKA. Discontinuation was defined as if a patient did not fill a consecutive prescription within 30 days after the expiration of a dispensed prescription [10, 21] .
Statistical analysis
Using the Aalen-Johansen estimator, the dynamics of the outcome-specific absolute risks (cumulative incidence) were calculated. Outcome-specific Cox models were combined with Cox models for mortality, discontinuation and shift of treatment to predict the absolute 1-year risks of outcome [22] . All Cox models were adjusted for calendar year and stratified for age (<65, 65-74, 75-84 and ≥85 years) and sex. For the stroke/TE and ischaemic stroke outcomes, the models were adjusted for heart failure, hypertension, diabetes mellitus, prior stroke/TE and vascular disease. For the bleeding outcomes, the models were additionally adjusted for abnormal renal or liver function, prior bleeding, antiplatelet drugs, non-steroidal anti-inflammatory drugs and alcohol abuse. All analyses were performed separately for the subset of patients who initiated standard and reduced dose NOAC, respectively. Results were reported as standardized differences in 1-year absolute risks of outcome between NOACs (average treatment effects) based on g-formula together with 95% bootstrap confidence limits (1000 bootstrap data sets) [22, 23] . Within the limitations of the available data, the average treatment effects can be interpreted as what one would have observed had the patients been randomized to dabigatran, rivaroxaban or apixaban [24] .
The level of significance was set at 5%.
Statistical analyses were performed in SAS (version 9.4, SAS Institute Inc. Gary, NC) and R [25] . 
Results
Study population
The final study population ( Fig. 1 ) included 31 522 AF patients initiating dabigatran standard dose (150 mg, n = 7078), dabigatran reduced dose (110 mg, n = 4414), rivaroxaban standard dose 
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(20 mg, n = 6868), rivaroxaban reduced dose (15 mg, n = 2098), apixaban standard dose (5 mg, n = 7203) and apixaban reduced dose (2.5 mg, n = 3861). Baseline characteristics are shown in Table 1 . The median age was higher in patients treated with standard dose rivaroxaban (71 years) and apixaban (71 years) than standard dose dabigatran (67 years). Moreover, the prevalence of chronic kidney disease and usage of antiplatelets was more frequent in patients treated with standard dose rivaroxaban and apixaban compared with standard dose dabigatran. A similar difference in patient characteristics was observed between patients treated with reduced dose rivaroxaban and apixaban versus reduced dose dabigatran.
Absolute risks
The unadjusted absolute risks including numbers at risks are illustrated in Fig. S1 . The standardized absolute risks of stroke/TE, major bleeding, intracranial bleeding and gastrointestinal bleeding for patients treated with standard and reduced dose are illustrated in Figs 2, 3, S2 and S3, respectively.
Patients receiving standard dose of NOAC were associated with a lower standardized absolute risk of all outcomes compared with reduced dose of NOAC. Overall, the standardized absolute risk of major bleeding was highest for rivaroxaban.
Comparisons of standard dose NOAC
For dabigatran, rivaroxaban and apixaban, the 1-year standardized absolute risks of stroke/TE were 1.73%, 1.73% and 1.98%, respectively, and of ischaemic stroke 1.02%, 0.91% and 0.99%, respectively ( Table 2 ). The absolute risk differences for stroke/TE and ischaemic stroke did not differ significantly when comparing NOACs pairwise.
For the major bleeding outcome, the 1-year standardized absolute risk was for rivaroxaban 2.78% (95% CI, 2.42% to 3.17%); the corresponding absolute risk differences were significantly lower for dabigatran -0.23% (95% CI, À0.41% to À0.06%) and for apixaban, À0.18% (95% CI, À0.34% to À0.01%). For intracranial bleeding, the 1-year standardized absolute risk was for dabigatran 0.19% (95% CI, 0.10 to 0.32%); the corresponding absolute risk differences were significantly increased for rivaroxaban with 0.23% (95% CI, 0.06% to 0.41%), and for apixaban with 0.18% (95% CI, 0.01% to 0.34%), but there was no significant difference in the absolute risks between rivaroxaban and apixaban.
Comparisons of reduced dose NOAC
The 1-year standardized absolute risks for reduced dose dabigatran, rivaroxaban and apixaban were for stroke/TE 2.51%, 2.70% and 2.78%, respectively, and for ischaemic stroke 1.28%, 1.52% and 1.29%, respectively (Table 3) . Again, the absolute risk differences were not significant in pairwise comparisons between NOACs.
The 1-year standardized absolute risks of major bleeding varied between NOACs, and rivaroxaban was associated with a significantly higher standardized absolute risk of major bleeding compared with dabigatran and apixaban. The risk of gastrointestinal bleeding was significantly lower for apixaban, and the 1-year standardized absolute risk was 1.50% (95% CI, 1.12% to 1.94%); the corresponding absolute risk differences were for dabigatran 0.68% (95% CI, 0.02% to 1.35%), and for rivaroxaban 0.87% (95% CI, 0.15% to 1.58%).
Discussion
In our nationwide cohort study of 31 522 OACna€ ıve AF patients initiating NOAC treatment, the associated stroke risks were similar in comparison with standard dose NOACs or in comparison with reduced dose NOACs. The bleeding risks varied between dabigatran, rivaroxaban and apixaban treatment. Rivaroxaban treatment was associated with an increased risk of major bleeding compared with the other NOACs. In a comparison of standard dose NOAC, dabigatran was associated with significantly lower risk of intracranial bleeding, and in a comparison of reduced dose NOAC, apixaban was associated with significantly lower risk of gastrointestinal bleeding.
Effectiveness between NOACs
We estimated the average treatment effects to imitate an RCT comparing standard dose NOACs or reduced dose NOACs. Other comparative observational studies, including a recently published study from our group, have compared NOACs versus VKA, and the studies found no difference in the association between stroke risk and dabigatran, rivaroxaban or apixaban compared with VKA [10] [11] [12] 26] . In the present study, we extend our prior observations [10] by showing that there was no absolute risk difference in the associated stroke risk between standard dose of NOAC or between reduced dose of NOAC. NOACs in AF / L. Staerk et al. [27] [28] [29] whereas a recently published American study by Noseworthy et al. compared dabigatran, rivaroxaban and apixaban in three one-to-one propensity-score-matched cohorts. The study found no difference in associated risk of stroke in the pairwise comparisons [30] . A major limitation in the study by Noseworthy et al. was the inability to compare across dabigatran, rivaroxaban and apixaban in only one analysis, as they used three one-to-one propensity-score-matched cohorts. Moreover, Noseworthy et al. did not separately compare standard or reduced dose NOAC.
Major bleeding risk
When studies point in a direction of no difference in effectiveness between the different NOACs, the succeeding clinical question is how to choose the safest NOAC treatment. In our study, rivaroxaban was associated with a higher risk of major bleeding compared with dabigatran or apixaban. The previously discussed American studies and a recently published meta-analysis also found an increased risk of bleeding associated with rivaroxaban compared with dabigatran [27, 28, 30, 31] . Two Danish studies by Larsen et al. [11] and Nielsen et al. [12] used VKA as reference and reported a significantly lower major bleeding risk associated with standard dose dabigatran and apixaban [11] and reduced dose dabigatran, respectively [12] . The two Danish studies did not compare across NOACs. Moreover, baseline covariates of patients receiving VKA influenced the inverse probability of treatmentweighted analysis. Other differences were that in our study all patients were first-time initiators of OAC, whereas in the studies by Larsen et al. [11] and Nielsen et al. [12] the inclusion criterion was those free of OAC treatment ≥1 year before entering The corresponding absolute risk differences test for significant differences between standardized absolute risks. Statistical significance is obtained when the 95% confidence limits for difference in absolute risks does not contain zero.
the study. Rivaroxaban is dosed once daily, whereas dabigatran and apixaban are dosed twice daily, and this could potentially contribute to the higher bleeding risk associated with rivaroxaban.
Intracranial bleeding
Meta-analyses based on the large Phase III RCTs have found lower risk of intracranial bleeding with NOACs and in conclusion the meta-analyses stated that the risk-benefit profile was more favourable with NOACs compared with VKA [13, 32] . Our group has previously published a study showing that dabigatran and apixaban were associated with lower risk of intracranial bleeding compared with VKA [10] . In a perspective of previously published studies [10, 27, 30] and the results from this study, dabigatran may have the lowest associated risk of intracranial bleeding compared with the other NOACs and VKA [6, 10, 26] . In Denmark, dabigatran was selected in less than 10% amongst all first-time users of OAC in December 2015 [2] .
Gastrointestinal bleeding
Intracranial bleedings more frequently causes death than gastrointestinal bleedings, but gastrointestinal bleedings are more frequent than intracranial bleedings amongst OAC-treated AF patients [6] [7] [8] 33 ]. In the RE-LY trial, [6] dabigatran 150 mg had an increased risk of gastrointestinal bleeding compared with warfarin, but other observational studies have not been able to find this association [34, 35] . In our study, the associated risk of gastrointestinal bleeding did not significantly differentiate between standard dose of NOACs, but reduced dose apixaban was associated with lower risk of gastrointestinal bleeding. Opposing results The corresponding absolute risk differences test for significant differences between standardized absolute risks. Statistical significance is obtained when the 95% confidence limits for difference in absolute risks does not contain zero.
were found in the American studies, which reported increased gastrointestinal bleeding risk with rivaroxaban versus dabigatran [27, 28] . The results in our study reflect all AF patients initiating NOAC treatment in a nationwide population, whereas the American studies were limited by including mostly patients >65 years. This may contribute to the differences in results as well as the fact that dabigatran 75 mg is recommended reduced dose in U.S., whereas in Denmark it is 110 mg [36] .
Reduced dose
In our study, the standardized absolute risks of stroke and bleeding were overall higher amongst patients initiating reduced dose NOAC than standard dose NOAC. This was also expected, because the Danish guidelines recommend dose reduction in selected patients, for example dabigatran 110 mg when age ≥80 years, concomitant treatment with verapamil, or high bleeding risk and low stroke risk; apixaban 2.5 mg when ≥2 criteria present of age ≥80 years, body weight ≤60 kg or serum creatinine ≥133 lmol L À1 [36] . We compared standard dose of NOAC and reduced dose of NOAC in two separate cohorts to avoid implanting a major confounding by indication bias; however, the differential thresholds for NOAC dose reduction could influence the risks of outcomes. We have previously shown that amongst those receiving reduced dose NOAC, 66.2% were ≥80 years (dabigatran 61.3%, rivaroxaban 64.3% and apixaban 77.1%) [10] . We do not have available data on body weight or blood tests in the Danish registries, and of that reason we could not examine if reduced dose was given according to guideline criteria. However, under-or overdosing of NOAC may have had an affect on our results, and a recent study showed that amongst NOAC-treated patients, 9.4% were underdosed, and 3.4% were overdosed [14] .
Clinical practice
Our study together with other comparative NOAC studies may contribute to guide AF patients and medical doctors to select between NOACs, for example choosing between dabigatran, rivaroxaban and apixaban in a case, where an AF patient has a high bleeding risk [27, 28, 30] . Moreover, our study reports standardized absolute risks of stroke and bleeding one year after initiation of NOAC treatment. Quantifying risk into an absolute risk instead of a relative risk might help AF patients and medical doctors in clinical practice to more intuitively understand the risk of stroke and bleeding when treated with NOACs.
Limitations
The major limitations of this study were due to the observational nature of the data. Residual confounding may have biased our results. We controlled for known confounders that were obtainable through the Danish registries, but we did not have data on potential confounders such as body weight, haemoglobin, international normalized ratio, serum creatinine and CrCl. The lack of data on kidney function may have influenced our results, as dabigatran is 80% renally excreted, thus, contraindicated for use when CrCL<30.
Confounding by indication is a concern in pharmacoepidemiologic studies. We attempted to minimize this limitation using g-formula and narrowing the selection of the study population to a more homogenous study population by only including patients with an AF diagnosis code registered prior to OAC initiation, exclude VKA and only compare NOACs, and include only firsttime initiators of OAC treatment. Patients initiating edoxaban (available in Denmark 19 June 2016) were not included (n = 33).
The number of events was small in some of the treatment groups, and reduced statistical power could have influenced our results in these analyses.
The Danish population is predominantly white, and the generalization of the study findings was limited to other populations similar to the Danish population.
Conclusions
This study examined AF patients, who initiated OAC for the first time. In comparison with standard dose NOAC, and, secondly, in comparison with reduced dose NOAC, the associated ischaemic stroke risk did not differ significantly, respectively. Standard dose and reduced dose of rivaroxaban were associated with increased risk of major bleeding compared with standard dose and reduced dose of the other NOACs, respectively. Standard dose dabigatran had the lowest associated risk of intracranial bleeding compared with standard dose of the other NOACs. There is a growing need for an RCT comparing the effectiveness and safety of NOACs amongst AF patients.
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